neuro-ophthalmology

ZUG, Switzerland, Aug. 3, 2026 Oculis announced that the U.S. Food and Drug Administration (FDA) has provided positive pre-Investigational...

October 14, 2025 | Zug, Switzerland — Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company advancing therapies for...